Jefferies' Aveo Pharmaceuticals Management Remains Confident in Differentiation From Inlyta - Provident Finl Servs (NYSE:PFS)

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Jefferies published a research report concerning Aveo Pharmaceuticals (NASDAQ: AVEO) recent management meeting. In the report, Jefferies states, “We had the opportunity to meet with AVEO management for an update on their thoughts post-release of top-line TIVO-1 results. We continue to believe that the 12-month progression free survival (PFS) and superior side effect profile will make tivo the new standard of care for renal cell carcinoma (RCC).”Jefferies maintains its Buy rating and $30 PT on Aveo Pharmaceuticals, which closed Friday at $14.83.

27% profit every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!